AI Article Synopsis
- HIV screening is recommended for everyone aged 13 to 64 years, and the study aimed to boost screening rates by routinely offering tests to all patients in a primary care clinic.
- During a 3-month period, 17% of patients accepted HIV testing, a significant rise from an earlier acceptance rate of less than 1%.
- The results suggest that making HIV screening a standard practice and involving trained staff can effectively increase the number of patients tested.
Article Abstract
Background: HIV screening is recommended for all patients between the ages of 13 and 64 years.
Objective: To increase the rate of HIV screening in a primary care setting by routinely offering HIV screening to all patients.
Methods: All patients seen over a 3-month period in the authors' clinic were offered HIV screening by a medical assistant.
Results: During the 3-month study period, 17% of patients offered HIV testing accepted screening, a large increase from the less than 1% rate of an earlier time period.
Conclusion: HIV screening can be increased by routinely offering the test to all patients in the office. Use of trained health care professionals other than physicians may increase the number of patients screened.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/2150131912448071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Estimating the economic consequences of leveraging the novel cobas® HIV-1/HIV-2 Qualitative NAT Test in routine HIV testing.
Clin Infect Dis
January 2025
IQVIA Inc., Falls Church, VA.
Article Synopsis
- The study compared the costs of the current CDC 3-step HIV testing algorithm with a new single-test alternative (cobas) for efficiency in diagnosing HIV.
- A decision-tree model estimated costs and testing needs for 1 million people, revealing significant reductions in total tests and retests required when using the alternative method.
- Findings indicate that the new algorithm could simplify HIV testing processes, cut overall testing numbers, and keep healthcare costs stable, thereby improving patient outcomes.
HIV-1 resistance mutations and genetic diversity among children failing antiretroviral treatment in five healthcare facilities in Benin, West Africa.
PLoS One
January 2025
Faculty of Sciences and Technology (FAST), Laboratory of Biology and Molecular Typing in Microbiology (LBTMM), University of Abomey-Calavi, Atlantic, Benin.
Background: Antiretroviral treatment increases the risk of accumulation of resistance mutations that negatively impact the possibilities of future treatment. This study aimed to present the frequency of HIV-1 antiretroviral resistance mutations and the genetic diversity among children with virological failure in five pediatric care facilities in Benin.
Methods: A cross-sectional study was carried out from November 20, 2020, to November 30, 2022, in children under 15 years of age who failed ongoing antiretroviral treatment at five facilities care in Benin (VL > 3log10 on two consecutive realizations three months apart).
Low cluster of differentiation 4+ T-cell count associated with thrombocytopenia among people living with human immunodeficiency virus-1 receiving antiretroviral in West Papua.
J Med Microbiol
January 2025
Midwifery Education Programme, Faculty of Health Sciences, Dr. Soebandi University, Jember, Indonesia.
Anaemia and thrombocytopenia are blood-related irregularities linked to an increased likelihood of disease progression, leading to death in people living with human immunodeficiency virus 1 (PLHIV). Severe clinical conditions associated with human immunodeficiency 1 (HIV-1) infection may be related to blood irregularities among PLHIV. The study aimed to examine the factors correlated with blood irregularities among PLHIV receiving antiretroviral treatment in West Papua.
View Article and Find Full Text PDFEvaluation of cervical cancer screening strategies in women living with HIV in Thailand.
Cancer Commun (Lond)
January 2025
Mortality, Health and Epidemiology Department, Institute for Demographic Studies (Ined), Aubervilliers, France.
Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials.
Clin Infect Dis
January 2025
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
Herpes simplex virus (HSV) infection is one of the most prevalent viral infections worldwide. In general, host immunity is sufficient to clear viral shedding and recurrences, although it is insufficient to prevent subsequent virologic reactivations. In immunocompromised patients, prolonged and difficult-to-treat HSV infections may develop.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!